continuous thermodilution and ANOCA endotypes; absolute coronary flow and TAVI; debating QFR; news from the EAPCI; and more.
This first-in-human study found that pre-emptive treatment of vulnerable lipid-rich plaques with a paclitaxel-coated balloon significantly reduced lipid burden, but larger randomized trials are needed to assess the clinical impact of this approach.
Patients with acute limb ischemia due to femoropopliteal stent thrombosis had significantly worse 12-month outcomes compared to those with acute limb ischemia from other causes, underscoring the importance of preventing stent thrombosis.
The article highlights the serious consequences of acute limb ischemia caused by stent thrombosis, and emphasizes the importance of minimizing stenting where possible, optimizing stent procedures, and ensuring proper antithrombotic therapy to prevent this complication.
Stents can exhibit significant unpredictable elongation during PCI of bifurcation lesions, especially in softer plaques, highlighting the importance of intravascular imaging to detect and manage this phenomenon.
The article provides a balanced overview of the current evidence comparing IVUS and OCT for guiding PCI. It notes that while IVUS has more robust clinical data supporting its use, especially for complex lesions, both modalities offer unique advantages and the choice should be individualized based on the specific clinical context and procedural goals.
The article discusses a new study, BIOMAG-II, that will assess whether the latest generation of resorbable magnesium scaffolds can match the performance of drug-eluting stents, which is essential to determine the future role of bioresorbable scaffold technology in revascularization procedures.
Don't miss our upcoming live X video chat on Outcomes of transcatheter aortic valve implantation for native aortic valve regurgitation with Chiara De Biase and Robin Le Ruz.
Join us on our social media channels, live on Thursday 3 October at 6:00 PM (CET - Paris time)
This study on the third-generation drug-eluting resorbable magnesium scaffold (DREAMS 3G) found that at 12 months, 99% of the scaffold struts became invisible on imaging, and the formation of protruding neointimal tissue, a unique finding with this scaffold, decreased significantly between 6 and 12 months, indicating favorable vascular healing over time.
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)